Compare Adaptive Biotechnologies Corp (ADPT) vs Global X NASDAQ 100 Covered Call ETF (QYLD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Global X NASDAQ 100 Covered Call ETF — how do they compare? Adaptive Biotechnologies Corp trades at $19.85 (market cap $3.33B), while Global X NASDAQ 100 Covered Call ETF trades at $18.06. Which is the better fit depends on your goals.
| ADPT | QYLD | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $22.37 | $18.52 |
52-Week Low | $10.24 | $16.46 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
QYLD trades at $18.34, up 1.38% with a bullish technical signal driven by moving averages, though oscillators remain neutral. The ETF's covered-call strategy generates high monthly dividends, with recent payouts of $0.19 and $0.18, but long-term performance has lagged the Nasdaq-100's growth. News highlights concerns over NAV erosion despite the 12% yield.
Outlook: High income appeals to retirees, but capital appreciation is limited by the covered-call structure. Risks include underperformance in bull markets and concentration in tech. Investors prioritize yield over growth, yet must monitor erosion risks highlighted by financial media.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Global X NASDAQ 100 Covered Call ETF
QYLD is an ETF that follows a covered call strategy on the NASDAQ 100 Index. The fund holds a long position in the stocks of the NASDAQ 100 and simultaneously writes (sells) call options on the index. The primary goal is to generate monthly income from the option premiums. This strategy can reduce portfolio volatility and provide income, but it limits potential capital appreciation from a significant rise in the NASDAQ 100 Index.
Read more on QYLD →
